| Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Co. has three platforms: its Oncology Innovation Platform, dedicated to the research and development of its proprietary drugs; its Commercial Platform, focused on the sales and marketing of its specialty drugs and the market development of its proprietary drugs; and its Global Supply Chain Platform, dedicated to providing a supply of active pharmaceutical ingredients for its clinical and commercial efforts. Co.'s clinical pipeline includes: Orascovery, Src Kinase inhibition, T-cell Receptor-engineered T-cells, and arginine deprivation therapy. We show 14 historical shares outstanding datapoints in our ATNX shares outstanding history coverage, used to compute ATNX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ATNX market cap history over the course of time is important for investors
interested in comparing ATNX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ATNX versus a peer is one thing; comparing
ATNX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ATNX can fluctuate over the course of history.
With this page we aim to empower investors researching ATNX by allowing them to research the ATNX market cap history.